TRCT
IBO

Tower Research Capital (TRC)’s Impact BioMedical IBO Stock Holding History

Tower Research Capital (TRC)’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,426
Closed -$720 – 5664
2025
Q4 		$720 Sell
1,426
-16
-1% -$8 ﹤0.01% 4834
2025
Q3 		$959 Sell
1,442
-7
-0.5% -$4 ﹤0.01% 4898
2025
Q2 		$938 Sell
1,449
-2,317
-62% -$1.3K ﹤0.01% 4906
2025
Q1 		$3.28K Buy
3,766
+6
+0.2% +$10 ﹤0.01% 4440
2024
Q4 		$5.45K Buy
+3,760
New +$7.8K ﹤0.01% 4285

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Tower Research Capital (TRC)'s IBO Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 1,426 shares — an estimated $720 sold.

Tower Research Capital (TRC) first reported a position in IBO in Q4 2024 and held it in 5 quarters. The position peaked at $5.45K in Q4 2024. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,426 Impact BioMedical shares in Q1 2026, an estimated $720.
  • Tower Research Capital (TRC) first reported a position in Impact BioMedical in Q4 2024 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s Impact BioMedical position peaked at $5.45K in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.